Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Toshiyuki Takasu"'
Autor:
Atsuo Tahara, Toshiyuki Takasu
Publikováno v:
Physiological Reports, Vol 7, Iss 22, Pp n/a-n/a (2019)
Abstract Nonalcoholic steatohepatitis (NASH) has become the most common cause of chronic liver disease worldwide in recent years. The pathogenesis of NASH is closely linked to metabolic diseases such as insulin resistance, obesity, dyslipidemia, and
Externí odkaz:
https://doaj.org/article/1822ccc0a0884007be7098a90fe52586
Publikováno v:
Journal of Pharmacological Sciences, Vol 131, Iss 3, Pp 198-208 (2016)
Previously we investigated the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan using normal and diabetic mice. We classified the SGLT2 inhibito
Externí odkaz:
https://doaj.org/article/88ea26e92666410a927c6a46af770f44
Publikováno v:
Journal of Pharmacological Sciences, Vol 130, Iss 3, Pp 159-169 (2016)
The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion. In the present study, the pharmacokinetic, pharmacodynamic, and pharmacologic properties
Externí odkaz:
https://doaj.org/article/bf0c238767b84d2fa8c3d4a9b7a5193d
Autor:
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Li Qun, Hiroshi Tomiyama, Yoshinori Kobayashi, Atsushi Noda, Masao Sasamata, Masayuki Shibasaki
Publikováno v:
Journal of Pharmacological Sciences, Vol 120, Iss 1, Pp 36-44 (2012)
Sodium-glucose cotransporter (SGLT) 2 plays an important role in renal glucose reabsorption, and inhibition of renal SGLT2 activity represents an innovative strategy for the treatment of hyperglycemia in diabetic patients. The present study investiga
Externí odkaz:
https://doaj.org/article/7343cab4fe994577b817d84f0d252634
Autor:
Kenichi Nakajima, Tomoya Mita, Yusuke Osonoi, Kosuke Azuma, Toshiyuki Takasu, Yoshio Fujitani, Hirotaka Watada
Publikováno v:
International Journal of Endocrinology, Vol 2015 (2015)
Epidemiological data suggest that postprandial hyperglycaemia and hypoglycaemia are potential risk factors for cardiovascular disease. However, the effects of repetitive postprandial glucose spikes, repetitive hypoglycaemia, and their combination on
Externí odkaz:
https://doaj.org/article/f81ddf31b6c24620ac21ec577791fb13
Autor:
Toshiyuki, Takasu
Publikováno v:
Biological and Pharmaceutical Bulletin. 45:1321-1331
Evidence from clinical trials suggests that the cardioprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors may arise through non-glycemic control-related mechanisms. Further, the cardiovascular advantages of SGLT2 inhibitors are li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f011b393b62dca3b38d1f9f246501304
https://doi.org/10.1248/bpb.b22-00289
https://doi.org/10.1248/bpb.b22-00289
Autor:
Toshiyuki Takasu, Shoji Takakura
Publikováno v:
Life Sciences. 230:19-27
Aims We investigated the effect of the selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin on cardiac dysfunction and histopathology in a non-diabetic rat model of cardiomyopathy. Main methods Ipragliflozin was mixed wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b173e47ea787d9d8ec0128a66af885
https://doi.org/10.1016/j.lfs.2019.05.051
https://doi.org/10.1016/j.lfs.2019.05.051
Publikováno v:
Biological and Pharmaceutical Bulletin. 42:507-511
Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. To date, the only known in vitro pharmacological characteristic of ipragliflozin is its selectivity for SGLT2 over SGL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bb6ae5fb47bb0e0faf429b3fbea81e9
https://doi.org/10.1248/bpb.b18-00728
https://doi.org/10.1248/bpb.b18-00728
Autor:
Toshiyuki Takasu, Shoji Takakura
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 46:266-273
The first dose of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor induces osmotic diuresis and can thereby affect cardiovascular activity in hyperglycemic patients. We aimed to determine whether the first dose of the selective SGLT2 inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67ea3412d9ef51711e44c6d6df629f5
https://doi.org/10.1111/1440-1681.13053
https://doi.org/10.1111/1440-1681.13053
Publikováno v:
Biomedicine & Pharmacotherapy. 105:1033-1041
Aims The sodium-glucose cotransporter (SGLT) 2 inhibitor, ipragliflozin, improves not only hyperglycemia but also obesity in type 2 diabetic animals and patients; however, there have been concerns that it may also cause an increase in compensatory fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea49f51cf90628a431fbbf956f8072c
https://doi.org/10.1016/j.biopha.2018.06.062
https://doi.org/10.1016/j.biopha.2018.06.062